US Clinical Trial NCT03949842

A Comparison of the Clinical Effectiveness of Inhaled Triple Therapy (Fluticasone Furoate / Umeclidinium Bromide / Vilanterol) in a Single Inhaler (TRELEGY™ ELLIPTA™) With Inhaled Non-ELLIPTA™ Multiple Inhaler Triple Therapies in COPD Patients in the US Within a Usual Care Setting in a Prospective Pre-Post Study  May 13, 2019

Parties

Contacts
Investigators
Sponsors
Keywords
COPD ELLIPTA Fluticasone furoate LEGEND MITT Pulmonary Disease, Chronic Obstructive SITT TRELEGY Umeclidinium bromide Vilanterol

JSON preview

Similar records

Title

Source:  NIH Last updated:  Jun 12, 2019

From ClinicalTrials.gov, a database of the U.S. National Institutes of Health, through its National Library of Medicine. This record may not reflect the most current and accurate biomedical/scientific data available from the NLM/NIH.